Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06248788 · ClinicalTrials.gov registry record
Salivary Immunoglobulin A (sIgA) Normal Range Study
A clinical trial, sponsored by 4Life Research.
- Completed
- Registry status
- 47
- Enrollment target
NCT06248788: Completed study, sponsored by 4Life Research.
NCT06248788 is a clinical trial that has completed, run by 4Life Research. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06248788 has completed, sponsored by 4Life Research.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
Salivary Immunoglobulin A (sIgA) is a marker of immune system activity. Typically, sIgA is determined by an ELISA test in which samples have to be sent to a specialized laboratory for testing. Investigators have developed a new instrument that is small, portable, and easy to use. This instrument is available for consumers to purchase and test their own sIgA at home.
Interventions
- DEVICE PoC Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2018-01-20 |
What the finished NCT06248788 record still lists
NCT06248788 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PoC Device is the first listed.
NCT06248788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06248788 about?
NCT06248788 is a clinical study titled "Salivary Immunoglobulin A (sIgA) Normal Range Study". Salivary Immunoglobulin A (sIgA) is a marker of immune system activity. Typically, sIgA is determined by an ELISA test in which samples have to be sent to a specialized laboratory for testing. Investigators have developed a new instrument that is small, portable, and easy to use. This instrument is ...
What is the current status of trial NCT06248788?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2017-06-19. Estimated completion is 2018-01-20.
What interventions are being tested in trial NCT06248788?
The interventions under investigation include: PoC Device (DEVICE).
Who is sponsoring clinical trial NCT06248788?
This trial is sponsored by 4Life Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI